Current Diabetes Reports

, Volume 13, Issue 4, pp 500–508 | Cite as

New and Developing Drugs for the Treatment of Neuropathic Pain in Diabetes

Microvascular Complications-Neuropathy (D Ziegler, Section Editor)


A number of agents from diverse pharmacological classes are used to treat neuropathic pain associated with diabetic peripheral neuropathy. Only three of these have regulatory approval for this indication in the U.S. In this focused article, I will discuss selected drugs, newly approved or in development, to treat neuropathic pain in patients with diabetic neuropathy. These will include agonists and antagonists of the transient receptor potential channels, a family of receptor proteins that play a role in the transduction of physical stress; sodium channel isoform specific antagonists; a recently approved dual-action opioid receptor agonist–norepinephrine reuptake inhibitor; gene therapy for neuropathic pain; and anti-nerve growth factor molecules. Mechanisms of action, preclinical supporting data, clinical trial evidence, and adverse effects will be reviewed.


Neuropathic pain Diabetic peripheral neuropathy TRPV1 TRPA1capsaicin Sodium channel antagonists NaV1.7 Anti-NGF antibodies Gene therapy Tapentadol Diabetes 



Roy Freeman has received grant support from the NIH.

Compliance with Ethics Guidelines

Conflict of Interest

Roy Freeman has been a consultant for Pfizer, Eli Lilly, Abbott, Bristol-Myers-Squibb, Chelsea, GlaxoSmithKline, Sanofi-Aventis, Depomed, and Johnson & Johnson.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976–82.PubMedCrossRefGoogle Scholar
  2. 2.
    Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10:393–400.PubMedCrossRefGoogle Scholar
  4. 4.
    Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31:464–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Freeman R. Pharmacotherapy of neuropathic pain. In: Simpson DM, McArthur JC, Dworkin RH, editors. Neuropathic Pain: Mechanisms, Diagnosis and Treatment. New York: Oxford University Press; 2012. p. 112–31.Google Scholar
  6. 6.
    Caterina MJ. Vanilloid receptors take a TRP beyond the sensory afferent. Pain. 2003;105:5–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Pingle SC, Matta JA, Ahern GP (2007) Capsaicin receptor: TRPV1 a promiscuous TRP channel. HandbExpPharmacol: 155–171Google Scholar
  8. 8.
    Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMCNeurol. 2007;7:11.Google Scholar
  9. 9.
    Lauria G, Morbin M, Lombardi R, et al. Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and in painful neuropathies. J Peripher Nerv Syst. 2006;11:262–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Derry S, Lloyd R, Moore RA, McQuay HJ (2009) Topical capsaicin for chronic neuropathic pain in adults. CochraneDatabaseSystRev: CD007393Google Scholar
  11. 11.
    Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81:135–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Simone DA, Nolano M, Johnson T, Wendelschafer-Crabb G, Kennedy WR. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci. 1998;18:8947–59.PubMedGoogle Scholar
  13. 13.
    Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain. 2004;127:1606–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Gibbons CH, Wang N, Freeman R. Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann Neurol. 2010;68:888–98.PubMedCrossRefGoogle Scholar
  15. 15.
    Wood JN, Winter J, James IF, Rang HP, Yeats J, Bevan S. Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture. J Neurosci. 1988;8:3208–20.PubMedGoogle Scholar
  16. 16.
    Sikand P, Premkumar LS. Potentiation of glutamatergic synaptic transmission by protein kinase C-mediated sensitization of TRPV1 at the first sensory synapse. J Physiol. 2007;581:631–47.PubMedCrossRefGoogle Scholar
  17. 17.
    Amantini C, Mosca M, Nabissi M, et al. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem. 2007;102:977–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328:991.PubMedCrossRefGoogle Scholar
  19. 19.
    Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21:265–70.PubMedCrossRefGoogle Scholar
  20. 20.
    (1992) Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group. Diabetes Care 15: 159–165Google Scholar
  21. 21.
    Tandan R, Lewis GA, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care. 1992;15:15–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Low PA, Opfer-Gehrking TL, Dyck PJ, Litchy WJ, O'Brien PC. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain. 1995;62:163–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15:510–26.PubMedGoogle Scholar
  24. 24.
    Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 1997;15:2974–80.PubMedGoogle Scholar
  25. 25.
    Watson CP, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain. 1992;51:375–9.PubMedCrossRefGoogle Scholar
  26. 26.
    • Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–12. The first pivotal trial demonstrating efficacy of a high-concentration capsaicin patch for the treatment of postherpetic neuralgia.PubMedCrossRefGoogle Scholar
  27. 27.
    Backonja MM, Malan TP, Vanhove GF, Tobias JK. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11:600–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12:99–109.PubMedCrossRefGoogle Scholar
  29. 29.
    Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain Off J Am Pain Soc. 2010;11:579–87.CrossRefGoogle Scholar
  31. 31.
    Jancso N, Jancso-Gabor A, Szolcsanyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother. 1967;31:138–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Schuller TB, Hermann K, Baron R. Quantitative assessment and correlation of sympathetic, parasympathetic, and afferent small fiber function in peripheral neuropathy. J Neurol. 2000;247:267–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Low VA, Sandroni P, Fealey RD, Low PA. Detection of small-fiber neuropathy by sudomotor testing. Muscle Nerve. 2006;34:57–61.PubMedCrossRefGoogle Scholar
  34. 34.
    Parkhouse N, Le Quesne PM. Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med. 1988;318:1306–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Berghoff M, Kilo S, Hilz MJ, Freeman R (2006) Differential impairment of the sudomotor and nociceptor axon-reflex in diabetic peripheral neuropathy. Muscle NerveGoogle Scholar
  36. 36.
    Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351:48–55.PubMedCrossRefGoogle Scholar
  37. 37.
    Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19:377–84.PubMedCrossRefGoogle Scholar
  38. 38.
    Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 1998;21:1071–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care. 1994;17:557–60.PubMedCrossRefGoogle Scholar
  40. 40.
    • Brederson JD, Kym PR, Szallasi A (2013) Targeting TRP channels for pain relief. Eur J Pharmacol. Review of current TRP channel therapeutic approaches.Google Scholar
  41. 41.
    Chen J, Joshi SK, DiDomenico S, et al. Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. Pain. 2011;152:1165–72.PubMedCrossRefGoogle Scholar
  42. 42.
    Andrade EL, Meotti FC, Calixto JB. TRPA1 antagonists as potential analgesic drugs. Pharmacol Ther. 2012;133:189–204.PubMedCrossRefGoogle Scholar
  43. 43.
    Kremeyer B, Lopera F, Cox JJ, et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron. 2010;66:671–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Waxman SG, Cummins TR, Dib-Hajj S, Fjell J, Black JA. Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Muscle Nerve. 1999;22:1177–87.PubMedCrossRefGoogle Scholar
  45. 45.
    Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev. 2005;57:397–409.PubMedCrossRefGoogle Scholar
  46. 46.
    Hains BC, Saab CY, Klein JP, Craner MJ, Waxman SG. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J Neurosci. 2004;24:4832–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Craner MJ, Klein JP, Renganathan M, Black JA, Waxman SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol. 2002;52:786–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Dib-Hajj SD, Fjell J, Cummins TR, et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain. 1999;83:591–600.PubMedCrossRefGoogle Scholar
  49. 49.
    Black JA, Cummins TR, Plumpton C, et al. Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. J Neurophys. 1999;82:2776–85.Google Scholar
  50. 50.
    Devor M, Govrin-Lippmann R, Angelides K. Na + channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci. 1993;13:1976–92.PubMedGoogle Scholar
  51. 51.
    Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain. 1992;48:261–8.PubMedCrossRefGoogle Scholar
  52. 52.
    • Fischer TZ, Waxman SG. Familial pain syndromes from mutations of the NaV1.7 sodium channel. Ann NY Acad Sci. 2010;1184:196–207. Review of the inherited pain syndromes associated with mutations in the NaV1.7 sodium channel. PubMedCrossRefGoogle Scholar
  53. 53.
    Dib-Hajj SD, Rush AM, Cummins TR, et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005;128:1847–54.PubMedCrossRefGoogle Scholar
  54. 54.
    Nilsen KB, Nicholas AK, Woods CG, Mellgren SI, Nebuchennykh M, Aasly J. Two novel SCN9A mutations causing insensitivity to pain. Pain. 2009;143:155–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Cregg R, Momin A, Rugiero F, Wood JN, Zhao J. Pain channelopathies. J Physiol. 2010;588:1897–904.PubMedCrossRefGoogle Scholar
  57. 57.
    •• Faber CG, Hoeijmakers JG, Ahn HS, et al. Gain of function Na(V) 1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol. 2012;71:26–39. First report suggestion that gain of functions NaV1.7 mutations may be present in idiopathic small-fiber neuropathies.PubMedCrossRefGoogle Scholar
  58. 58.
    Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG. Small-fibre neuropathies-advances in diagnosis, pathophysiology and management. Nat Rev Neurol. 2012;8:369–79.PubMedCrossRefGoogle Scholar
  59. 59.
    Chattopadhyay M, Zhou Z, Hao S, Mata M, Fink DJ. Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy. Molecular pain. 2012;8:17.PubMedCrossRefGoogle Scholar
  60. 60.
    Chattopadhyay M, Mata M, Fink DJ. Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci Off J Soc Neurosci. 2008;28:6652–8.CrossRefGoogle Scholar
  61. 61.
    Nassar MA, Baker MD, Levato A, et al. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol Pain. 2006;2:33.PubMedCrossRefGoogle Scholar
  62. 62.
    Nassar MA, Levato A, Stirling LC, Wood JN. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol Pain. 2005;1:24.PubMedCrossRefGoogle Scholar
  63. 63.
    Ossipov MH, Lai J, King T, et al. Antinociceptive and nociceptive actions of opioids. J Neurobiol. 2004;61:126–48.PubMedCrossRefGoogle Scholar
  64. 64.
    Pasternak GW. Molecular insights into mu opioid pharmacology: From the clinic to the bench. Clin J Pain. 2010;26 Suppl 10:S3–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology. 2003;60:927–34.PubMedCrossRefGoogle Scholar
  66. 66.
    Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837–41.PubMedCrossRefGoogle Scholar
  67. 67.
    Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59:1015–21.PubMedCrossRefGoogle Scholar
  69. 69.
    Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223–32.PubMedCrossRefGoogle Scholar
  70. 70.
    Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34.PubMedCrossRefGoogle Scholar
  71. 71.
    Gassner M, Ruscheweyh R, Sandkuhler J. Direct excitation of spinal GABAergic interneurons by noradrenaline. Pain. 2009;145:204–10.PubMedCrossRefGoogle Scholar
  72. 72.
    Tzschentke TM, Christoph T, Kogel B, et al. (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265–76.PubMedCrossRefGoogle Scholar
  73. 73.
    Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic alpha(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain. 2011;152:131–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Christoph T, De Vry J, Tzschentke TM. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett. 2010;470:91–4.PubMedCrossRefGoogle Scholar
  75. 75.
    Schroder W, Vry JD, Tzschentke TM, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain (London, England). 2010;14:814–21.CrossRefGoogle Scholar
  76. 76.
    Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009;25:765–76.PubMedCrossRefGoogle Scholar
  77. 77.
    Hoy SM. Tapentadol extended release: in adults with chronic pain. Drugs. 2012;72:375–93.PubMedCrossRefGoogle Scholar
  78. 78.
    Hartrick CT, Rozek RJ. Tapentadol in pain management: a mu-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS drugs. 2011;25:359–70.PubMedCrossRefGoogle Scholar
  79. 79.
    •• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151–62. One of two pivotal randomized-withdrawal design trials demonstrating the efficacy of tapentadol ER in the treatment of painful diabetic peripheral neuropathy. PubMedCrossRefGoogle Scholar
  80. 80.
    Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain. 2007;23:103–18.PubMedCrossRefGoogle Scholar
  81. 81.
    Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146:116–27.PubMedCrossRefGoogle Scholar
  82. 82.
    Fink DJ, Wolfe D. Gene Therapy for Pain: A Perspective. Pain Manag. 2011;1:379–81.PubMedCrossRefGoogle Scholar
  83. 83.
    •• Simonato M, Bennett J, Boulis NM, et al. (2013) Progress in gene therapy for neurological disorders. Nature reviews Neurology Overview of current issues and strategies in gene therapy for neurological disorders.Google Scholar
  84. 84.
    Wolfe D, Mata M, Fink DJ. Targeted drug delivery to the peripheral nervous system using gene therapy. Neurosci Lett. 2012;527:85–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Goins WF, Cohen JB, Glorioso JC. Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiol Dis. 2012;48:255–70.PubMedCrossRefGoogle Scholar
  86. 86.
    Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther Clin J Am Society Gene Ther. 2009;17:13–8.CrossRefGoogle Scholar
  87. 87.
    • Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol. 2011;70:207–12. First gene therapy trial for neuropathic pain. PubMedCrossRefGoogle Scholar
  88. 88.
    Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem. 1996;119:591–600.PubMedCrossRefGoogle Scholar
  89. 89.
    Yang XM, Toma JG, Bamji SX, et al. Autocrine hepatocyte growth factor provides a local mechanism for promoting axonal growth. J Neurosci Off J Soc Neurosci. 1998;18:8369–81.Google Scholar
  90. 90.
    Gascon E, Gaillard S, Malapert P, et al. Hepatocyte growth factor-Met signaling is required for Runx1 extinction and peptidergic differentiation in primary nociceptive neurons. J Neurosci Off J Soc Neurosci. 2010;30:12414–23.CrossRefGoogle Scholar
  91. 91.
    Ajroud-Driss S, Christiansen M, Allen JA, Kessler JA (2013) Phase 1/2 Open-label Dose-escalation Study of Plasmid DNA Expressing Two Isoforms of Hepatocyte Growth Factor in Patients With Painful Diabetic Peripheral Neuropathy. Molecular therapy : the journal of the American Society of Gene TherapyGoogle Scholar
  92. 92.
    Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115:189–204.PubMedCrossRefGoogle Scholar
  93. 93.
    Rotthier A, Baets J, Timmerman V, Janssens K. Mechanisms of disease in hereditary sensory and autonomic neuropathies. Nat Rev Neurol. 2012;8:73–85.PubMedCrossRefGoogle Scholar
  94. 94.
    Capsoni S, Covaceuszach S, Marinelli S, et al. Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. PLoSOne. 2011;6:e17321.Google Scholar
  95. 95.
    Obata K, Katsura H, Sakurai J, et al. Suppression of the p75 neurotrophin receptor in uninjured sensory neurons reduces neuropathic pain after nerve injury. J Neurosci Off J Soc Neurosci. 2006;26:11974–86.CrossRefGoogle Scholar
  96. 96.
    Smeyne RJ, Klein R, Schnapp A, et al. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature. 1994;368:246–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Crowley C, Spencer SD, Nishimura MC, et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell. 1994;76:1001–11.PubMedCrossRefGoogle Scholar
  98. 98.
    Indo Y. Genetics of congenital insensitivity to pain with anhidrosis (CIPA) or hereditary sensory and autonomic neuropathy type IV. Clinical, biological and molecular aspects of mutations in TRKA(NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Clin Auton Res. 2002;12 Suppl 1:I20–32.PubMedCrossRefGoogle Scholar
  99. 99.
    Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet. 1996;13:485–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Houlden H, King RH, Hashemi-Nejad A, et al. A novel TRK A (NTRK1) mutation associated with hereditary sensory and autonomic neuropathy type V. Ann Neurol. 2001;49:521–5.PubMedCrossRefGoogle Scholar
  101. 101.
    McMahon SB, Bennett DL, Priestley JV, Shelton DL. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med. 1995;1:774–80.PubMedCrossRefGoogle Scholar
  102. 102.
    McMahon SB. NGF as a mediator of inflammatory pain. Philos Trans R Soc B-Biol Sci. 1996;351:431–40.CrossRefGoogle Scholar
  103. 103.
    Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience. 1994;62:327–31.PubMedCrossRefGoogle Scholar
  104. 104.
    Gerber RK, Nie H, Arendt-Nielsen L, Curatolo M, Graven-Nielsen T. Local pain and spreading hyperalgesia induced by intramuscular injection of nerve growth factor are not reduced by local anesthesia of the muscle. Clin J Pain. 2011;27:240–7.PubMedCrossRefGoogle Scholar
  105. 105.
    •• Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521–31. Proof-of-concept trial using antibody to NGF to treat pain due to osteoarthritis.PubMedCrossRefGoogle Scholar
  106. 106.
    Ackermann PW (2012) Katz et al., efficacy and safety of tanezumab in the treatment of chronic low back pain [Pain 2011;152:2248–2258] and Hill, blocking the effects of NGF as a route to safe and effective pain relief - fact or fancy? [Pain 2011;152:2200–2201]. Pain 153: 1128–1129; author reply 1129–1131Google Scholar
  107. 107.
    Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185:1716–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Center for Autonomic and Peripheral Nerve DisordersBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations